SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

12 Aug 2022 Evaluate
The sales figure stood at Rs. 1013.55 millions for the June 2022 quarter. The mentioned figure indicates a growth of about 31.73% as compared to Rs. 769.42 millions during the year-ago period.The Total revenue for the quarter ended June 2022 of  Rs. 252.50  millions  grew by 226.27% from Rs. 77.39 millions.The company reported a good operating profit of 336.03 millions compared to 173.92 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1013.55 769.42 31.73 1013.55 769.42 31.73 5300.49 3912.45 35.48
Other Income 23.57 19.39 21.56 23.57 19.39 21.56 75.77 49.77 52.24
PBIDT 336.03 173.92 93.21 336.03 173.92 93.21 2215.62 1781.51 24.37
Interest 5.81 9.74 -40.35 5.81 9.74 -40.35 41.98 40.80 2.89
PBDT 330.22 164.18 101.13 330.22 164.18 101.13 2173.64 1740.71 24.87
Depreciation 28.85 24.77 16.47 28.85 24.77 16.47 101.18 67.61 49.65
PBT 301.37 139.41 116.18 301.37 139.41 116.18 2072.46 1673.10 23.87
TAX 48.87 62.02 -21.20 48.87 62.02 -21.20 554.35 437.16 26.81
Deferred Tax 3.00 45.97 -93.47 3.00 45.97 -93.47 32.46 6.94 367.72
PAT 252.50 77.39 226.27 252.50 77.39 226.27 1518.11 1235.94 22.83
Equity 160.96 146.37 9.97 160.96 146.37 9.97 160.97 146.37 9.97
PBIDTM(%) 33.15 22.60 46.67 33.15 22.60 46.67 41.80 45.53 -8.20

Supriya Lifescience Share Price

628.00 -9.30 (-1.46%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×